18 results about "Use insulin" patented technology

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.

The present invention relates to insulin analogs, particularly insulin analogs having shortened B chains. The present invention also relates to the crystal structure of insulin from the venom of cone snails and to methods of using the crystal and related structural information to screen for and design insulin analogs that interact with or modulate the insulin receptor. The present invention also relates to therapeutic and prophylactic methods using insulin analogs.

Described herein are compositions and methods for treating a disease or disorder associated with PI3K signaling. For example, such compositions can include use of modulators of glucose metabolism, use of at least one kinase in the insulin-receptor / PI3K / AKT / mTOR pathway, and / or use of diet that influences the subject's metabolic state.

The utility model provides a fixed application for an insulin pump, which relates to the technical field of medical instruments, and comprises an application, the application is used for fixing an infusion needle of the insulin pump, the infusion needle penetrates through the middle position in the application, one side of the infusion needle is connected with an infusion catheter, and the other side of the infusion needle is connected with an infusion tube. A fastening adhesive tape is arranged on the outer surface of the infusion catheter, and the fastening adhesive tape is used for fixing the infusion catheter; through the arrangement of the application and the fastening adhesive tape, the infusion needle head can be firmly fixed in the insulin pump, the fixing effect and the wearing comfort of the insulin pump are effectively improved, adverse effects of skin are reduced, and a better guarantee is provided for a patient to use the insulin pump.

The utility model relates to the technical field and discloses a multifunctional insulin pen. The multifunctional insulin pen comprises a driving tube, a pushing rod, a core sleeve, a needle head and a protective sleeve. A driving assembly is arranged in the driving pipe, and the driving pipe is movably connected with the pushing rod through the driving assembly; the pushing rod comprises an outer pushing pipe and an inner pushing rod; the inner push rod is movably connected with the outer push tube, the core sleeve is detachably connected with the outer push tube, one end of the inner push rod is located in the core sleeve, the other end of the core sleeve is detachably connected with the needle head, and the protective sleeve is detachably connected with the needle head. Guiding can be provided when a patient uses insulin, automatic injection can be achieved, and the injection time efficiency is fully guaranteed.

This invention belongs to the field of fungal polysaccharide application technology, specifically relating to a method for preparing and applying polysaccharide from *Boletus globosum*. Crude polysaccharide was extracted from the fruiting body of *Boletus globosum* using hot water extraction, and purified using DEAE-52 cellulose column chromatography. Subsequently, by establishing an alcohol-induced liver injury model, it was found that NOP-1 significantly reduced ALT and AST levels, while simultaneously decreasing MDA content and increasing SOD activity and GSH levels, indicating that NOP-1 can inhibit lipid peroxidation, enhance the antioxidant defense capacity of hepatocytes, and maintain hepatocyte membrane integrity. A HepG2 cell IR model was constructed using a high-glucose, high-insulin combined induction method, determining the optimal dosage of NOP-1. ‑6 Treatment of HepG2 cells with mol / L insulin for 24 h successfully induced insulin resistance. Glucose consumption experiments in IR HepG2 cells demonstrated that NOP-1 significantly enhanced the glucose consumption capacity of insulin-resistant cells, exhibiting significant in vitro hypoglycemic activity.

An example system for therapy delivery includes one or more processors configured to in response to a prediction indicating that the meal event is to occur, output instructions to an insulin delivery device to deliver a partial therapy dosage, to a device to notify the patient to use the insulin delivery device to take the partial therapy dosage, or to the insulin delivery device to prepare the partial therapy dosage prior to the meal event occurring, and in response to a determination indicating that the meal event is occurring (e.g., based on movement characteristics of a patient arm), output instructions to the insulin delivery device to deliver a remaining therapy dosage, to the device to notify the patient to use the insulin delivery device to take the remaining therapy dosage, or to the insulin delivery device to prepare the remaining therapy dosage.

The invention relates to the field of medical instruments, in particular to an automatic insulin use assisting device and an application method thereof.The automatic insulin use assisting device comprises a control cylinder, an insulin pushing assembly is connected to the interior of the control cylinder, and an insulin pen fixing assembly is connected to the outer side of the lower end of the control cylinder and used for fixing an insulin pen; an exhaust monitoring assembly is connected to the outer sides of the control cylinder and the insulin pen fixing assembly. The insulin dosage can be automatically set, and the problem that patients with visual impairment and old people are difficult to accurately set the dosage is solved; due to the automatic exhaust function, the insulin injection accuracy is guaranteed, and injection errors caused by air residues are reduced; the voice broadcast function is convenient for old people and patients with visual impairment to use the insulin pen; the function associated with the mobile phone enables family members to know the insulin use condition of the patient in real time; through the detachable and recyclable design of the device arranged in the scheme, the economic burden of the patient is relieved.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The present disclosure provides compositions including a polyacrylamide-based copolymer, one or more preservatives, and insulin or an analog thereof. Also provided are methods of using the insulin compositions, including methods of administering the compositions to a human subject in need thereof.

An insulin fluorescence immunoassay kit provided by the present application and its preparation method use an insulin monoclonal antibody and a chicken IgY antibody as the antibodies for coating on the test line and the quality control line respectively, and a mixture of the insulin monoclonal antibody and a goat anti-chicken IgY antibody as the fluorescent microsphere-labeled antibody. Using the fluorescence immunoassay method, compared with the currently commonly used insulin detection methods such as enzyme-linked immunosorbent assay (ELISA) / radioimmunoassay (RIA), it not only greatly shortens the detection time and reduces the detection cost, but also improves the detection sensitivity. Compared with similar methods, it has the advantages of simple labeling process, high sensitivity, and accurate results. By designing experiments, suitable materials for preparing the test strip are selected. The preparation process is simple. The prepared kit has high detection sensitivity, accurate and stable results, low detection cost, easy use of the product, and low manufacturing cost, and is suitable for mass production.

A system and method provides a glucose report for determining glycemic risk based on an ambulatory glucose profile of glucose data over a time period, a glucose control assessment based on median and variability of glucose, and indicators of high glucose variability. Time of day periods are shown at which glucose levels can be seen. A median glucose goal and a low glucose line provide coupled with glucose variability provide a view into effects that raising or lowering the median goal would have. Likelihood of low glucose, median glucose compared to goal, and variability of glucose below median provide probabilities based on glucose data. Patterns can be seen and provide guidance for treatment.

The invention discloses application of insulin in regulation and control of LC-PUFA (liquid chromatography-polyunsaturated fatty acid) biosynthesis of eriocheir sinensis, and belongs to the technical field of bioengineering. The invention provides an application of insulin in preparation of a preparation for regulating and controlling eriocheir sinensis LC-PUFA biosynthesis, insulin is taken as an active component, and the content of LC-PUFA is regulated and controlled in a targeted manner by improving the PIK3Ralpha gene expression of eriocheir sinensis. The invention further provides application of the combination of the insulin and the PI3K agonist 740Y-P in preparation of a preparation for regulating and controlling the LC-PUFA biosynthesis of the eriocheir sinensis. The invention also provides a preparation for regulating and controlling the LC-PUFA biosynthesis of the eriocheir sinensis, which comprises an effective amount of insulin as an active component and also comprises a PI3K agonist 740Y-P. Experiments prove that the insulin regulates and controls the LC-PUFA biosynthesis of the eriocheir sinensis in a targeted manner through a PIK3 signal channel, and a general strategy is provided for nutrition regulation and control of crustaceans.

The invention discloses a method and equipment for calculating the injection dose of a periinsulin preparation. The method comprises the following steps: acquiring a single injection pharmacokinetic model of the periinsulin preparation, historical injection information of a patient using the periinsulin preparation, a fasting blood glucose value monitored during the period of using the periinsulin preparation by the patient and a dose estimated value of the injection; according to the acquired single injection pharmacokinetic model, the historical injection information, the fasting blood glucose value and the dose estimation value, predicting fasting blood glucose of the patient in a next week after the patient injects the periinsulin preparation according to the dose estimation value; according to whether the fasting blood glucose of the next week is within the fasting blood glucose target range of the patient or not, whether the dose estimation value needs to be adjusted or not is judged, and the dose estimation value is adjusted based on the judgment result so that the adjusted injection dose estimation value can meet the requirement. The injection dosage can enable a patient to reach a steady state as soon as possible, and the injection dosage can be compatible with occasionally irregular injection modes.